Shares of Neos Therapeutics NEOS rose 4.2% in pre-market trading after the company reported Q2 results.
Quarterly Results
Earnings per share decreased 37.50% over the past year to ($0.11), which beat the estimate of ($0.13).
Revenue of $13,133,000 declined by 16.05% year over year, which beat the estimate of $12,170,000.
Guidance
Neos Therapeutics hasn't issued any earnings guidance for the time being.
Neos Therapeutics hasn't issued any revenue guidance for the time being.
How To Listen To The Conference Call
Date: Aug 10, 2020
Time: 08:30 AM
ET Webcast URL: https://edge.media-server.com/mmc/p/zyx7gcty
Recent Stock Performance
52-week high: $2.15
52-week low: $0.60
Price action over last quarter: down 10.70%
Company Profile
Neos Therapeutics Inc is a pharmaceutical company, engaged in the development, manufacture, and commercialization of products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technologies. The product portfolio of the company includes Methylphenidate XR-ODT and Amphetamine XR oral suspension commonly prescribed medicine for the treatment of ADHD. In addition, it also manufactures and markets generic Tussionex, a hydrocodone polistirex and chlorpheniramine polistirex XR liquid suspension product indicated for the relief of cough. Geographically, it operates through the United States and derives revenue through the sale of products.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.